SER supply chain intelligence for Serina Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Serina Therapeutics, Inc. (SER) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BOARD-OF-DIRECTORS | BOARD-OF-DIRECTORS | 90% | On September 9, 2025, the Company entered into an unsecured convertible note (the “2025 Convertible Note”) with a member of the Company’s Board of Directors, providing for aggregate borrowing of up t… |
| INVESTORS | INVESTORS | 90% | On March 19 and 20, 2026, the investors funded the full $ 15.0 million of the first closing, and the Company issued 0.4 million shares of common stock, 6.2 million Pre-Funded Warrants and 3.3 million… |
| JUVENESCENCE | JUVENESCENCE | 90% | Juvenescence exercised Post-Merger Warrants to purchase 377,865 shares of the Company’s common stock at an exercise price of $ 13.20 per share, for a total purchase price of $ 5.0 million. |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and r… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BOARD-OF-DIRECTORS | BOARD-OF-DIRECTORS | 85% | On March 17, 2026, the Company entered into the March 2026 PIPE, a private placement of common stock and pre-funded warrants led by a member of the Board of Directors, at $2.25 per share. |
| INVESTORS | INVESTORS | 85% | The Company entered into a Registration Rights Agreement with the investors pursuant to which the Company agreed to file a registration statement covering the resale of the registrable securities no … |
| JUVENESCENCE | JUVENESCENCE | 80% | In connection with Agreement, the Company issued to Juvenescence warrants to purchase 755,728 shares of common stock at an exercise price of $ 18.00 per share (the “Replacement Incentive Warrants” an… |
| NEUROAIRMID-THERAPEUTICS-INC | NEUROAIRMID-THERAPEUTICS-INC | 62% | nterim financial statements. As such, there is substantial doubt about the Company’s ability to continue as a going concern. The Company is subject to risks and uncertainties common to early-stage co… |
| SECURITIES-INVESTOR-PROTECTION-CORPORATION | SECURITIES-INVESTOR-PROTECTION-CORPORATION | 62% | operations will be affected. Foreign currency translation and transactions The Company’s reporting currency is the U.S. dollar. The functional currency of the Company’s subsidiary located in Australi… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SER-DEBT-12470 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| SER-DEBT-12469 | Warrants outstanding: 53980 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| SER-DEBT | Debt stack $11.2M | 90% | Market cache reports total debt of $11.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SER-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 12,758; ownership 0.12%; value $28,960; as of 2025-12-31. |
| SER-OWNER-LINSCOMB-WEALTH-INC | Linscomb Wealth, Inc. | 95% | 13F/ownership overlay lists Linscomb Wealth, Inc.; shares held 18,800; ownership 0.17%; value $42,675; as of 2025-12-31. |
| SER-OWNER-WAVERLY-ADVISORS-LLC | Waverly Advisors, LLC | 95% | 13F/ownership overlay lists Waverly Advisors, LLC; shares held 67,492; ownership 0.63%; value $153,206; as of 2025-12-31. |
| SER-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 17,249; ownership 0.16%; value $39,155; as of 2025-12-31. |
| SER-OWNER-BROADWOOD-CAPITAL-INC | Broadwood Capital, Inc. | 95% | 13F/ownership overlay lists Broadwood Capital, Inc.; shares held 54,484; ownership 0.51%; value $123,678; as of 2025-12-31. |
| SER-OWNER-KEEL-POINT-LLC | Keel Point, Llc | 95% | 13F/ownership overlay lists Keel Point, Llc; shares held 17,774; ownership 0.16%; value $40,346; as of 2025-12-31. |
| SER-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 30,409; ownership 0.28%; value $69,028; as of 2025-12-31. |
| SER-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 180,013; ownership 1.67%; value $408,629; as of 2025-12-31. |
| SER-OWNER-HIGHTOWER-ADVISORS-LLC | HighTower Advisors, LLC | 95% | 13F/ownership overlay lists HighTower Advisors, LLC; shares held 11,980; ownership 0.11%; value $27,194; as of 2025-12-31. |
| SER-OWNER-NORTHERN-TRUST-CORPORATION | Northern Trust Corporation | 95% | 13F/ownership overlay lists Northern Trust Corporation; shares held 14,082; ownership 0.13%; value $31,966; as of 2025-12-31. |
| SER-OWNER-SIO-CAPITAL-MANAGEMENT-LLC | Sio Capital Management, LLC | 90% | 13F overlay lists Sio Capital Management, LLC as top holder; 25 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | 100.00 | 2 | |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| JHG | Janus Henderson Group plc | 100.00 | 2 | |
| APAM | Artisan Partners Asset Management Inc. | 100.00 | 2 | |
| ASND | Ascendis Pharma A/S | 100.00 | 1 | ['supplier'] |
| SNYNF | Sanofi | 100.00 | 2 | |
| NKTR | Nektar Therapeutics | 100.00 | 2 | |
| OPK | OPKO Health, Inc. | 100.00 | 2 |